Presumably, the nondepleting and inhibitory CD19 mAb impairs CD19–CXCR4 signaling crosstalk even with the lack of tumor-invading effector cells and prevents the further dissemination of malignant B cells. This evidence concerns the gene CD19 and neoplasm.